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Here we provide evidence that WNT-3a modulates platelet function by regulating the activity of four
key GTPase proteins: Rap1, Cdc42, Rac1 and RhoA. We observe WNT-3a to differentially regulate
small GTPase activity in platelets, promoting the GDP-bound form of Rap1b to inhibit integrin-aIIbb3
adhesion, while concomitantly increasing Cdc42 and Rac1-GTP levels thereby disrupting normal
platelet spreading. We demonstrate that Daam-1 interacts with Dishevelled upon platelet activation,
which correlates with increased RhoA-GTP levels. Upon pre-treatment with WNT-3a, this complex
disassociates, concurrent with a reduction in RhoA-GTP. Together these data implicate WNT-3a as
a novel upstream regulator of small GTPase activity in platelets.
Structured summary of protein interactions:
DVL physically interacts with DAAM-1 by anti bait co-immunoprecipitation (View interaction)
DVL and DAAM-1 colocalise by ﬂuorescence microscopy (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction traditionally thought to be a canonical ligand, emerging evidenceAnucleate platelets are the principal effectors of haemostasis
and are found circulating in a non-adhesive, quiescent state. Small
GTPase proteins such as Rho, Rac and Rap play an important signal-
ling role during platelet activation where they regulate a variety of
intracellular functions including integrin activation, stress ﬁbre
formation and cytoskeletal reorganisation [1–3]. GTPases cycle be-
tween an active and inactive state, regulated by Guanine nucleo-
tide Exchange Factors (GEFs) and GTPase Activating Proteins
(GAPs). In resting platelets, small GTPase proteins exist mainly in
a GDP-bound state, with GAPs promoting the hydrolysis of GTP
to GDP. Upon platelet stimulation, GEFs then promote their activa-
tion by increasing the binding of GTP. This allows the GTPase pro-
tein to bind its effector and so initiate a signalling response [4,5].
We have previously shown the canonical WNT signalling path-
way to be present and active in platelets and the WNT-3a ligand to
inhibit platelet adhesion, secretion and shape change during the
platelet activation response [6]. The Frizzled-6 (Fzd6) receptor
was shown in part to mediate this inhibitory response; however
the underlying signalling effect and the exact downstream WNT
signalling effectors involved are currently unknown. Althoughchemical Societies. Published by E
titute, School of Biomolecular
reland. Fax: +353 1 7166700.
le), patricia.maguire@ucd.iesuggests that WNT-3a may also activate non-canonical pathways
to regulate small GTPase activity [7–10]. In particular, it has been
shown that WNT-3a regulates RhoA-GTP levels by engaging Fzd
receptors to regulate the interaction between the cytoplasmic
WNT signalling protein Dishevelled (Dvl) and the formin protein
Daam-1 [11–13].
In platelets, a number of formin-related proteins are known to
be present, including mDia1, mDia2, Fhod1 and Daam-1 [14].
Although Daam-1 is known to promote actin assembly through
the small GTPase RhoA [15], the upstream signalling processes that
regulate Daam-1 activity in platelets are currently unknown. In
other cell types, the formation of a Dvl/Daam-1 complex is critical
for RhoA activation, since Daam-1 does not have the ability to acti-
vate RhoA on its own. Instead Daam-1 is thought to act as a scaf-
fold protein, ﬁrst binding to Dvl to allow ‘unfolding’ of the
protein, before recruiting Rho GEF proteins to enhance GTPase acti-
vation [12]. This activates the downstream effector Rho-associated
kinase (ROCK), which mediates cytoskeletal rearrangement by pro-
moting myosin light chain phosphorylation [5,16]. As we previ-
ously identiﬁed Dvl in human platelets and found WNT-3a to
reduce platelet RhoA-GTP levels [6], we hypothesised a link be-
tween WNT signalling in platelets and small GTPase function.
Here we provide evidence that WNT-3a is differentially modu-
lating the activity of four key platelet GTPase proteins: Rap1,
Cdc42, Rac1 and RhoA. Furthermore, we demonstrate that
WNT-3a regulates a Dvl/Daam-1 signalling complex in plateletslsevier B.V. All rights reserved.
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GTPase activity byWNT-3a can have a major impact on the platelet
signalling response and represents a possible mechanism through
which WNT signalling negatively regulates platelet function.
2. Methods
2.1. Platelet isolation and co-immunoprecipitation
Platelets were isolated by centrifugation and recombinant
WNT-3a (R&D Systems, Abingdon, UK) added 30 s before agonist
loading as previously described [6]. Platelet activation was for
30 s unless otherwise stated and co-immunoprecipitation experi-
ments carried out on the lysed platelets (1  109/ml) as before
[17] using an antibody speciﬁc for anti-Dvl (sc-25534, Santa Cruz,
Heidelberg, Germany). Recombinant WNT-3a vehicle controls
were tested in a wide range of platelet assays, with no signiﬁcant
effects observed.
2.2. Measurement of small GTPase activation
Washed platelets (1  109/ml) were activated with 1.5 lM
TRAP for 30 s before lysis. 20 ll lysate was kept for analysis of total
protein expression and the remaining lysate used to precipitate
GTP-bound protein using agarose beads conjugated to either
GST-Rhotekin-RBD for RhoA (Cytoskeleton, CO, USA), GST-PAK-
PBD for Rac1 (Cytoskeleton) or GST-RalGDS-RBD for Rap1b as pre-
viously described [18]. Total and precipitated GTPase protein was
measured by immunoblot analysis as per the manufacturer’s
instructions. GTP-bound Cdc42 protein was measured using a G-
LISA assay (Cytoskeleton).
2.3. SDS–PAGE and immunoblotting
Equal amounts of protein were analysed by Western blotting
and visualised as described [6]. Antibodies used were as follows:
Abcam (Cambridge, UK): GAPDH (ab9485); Santa Cruz (Heidelberg,
Germany): a-actinin (sc-17829), b-actin (sc-130300), Dvl (sc-
25534), RhoA (sc-418) and Rap1 (sc-166556); Cytoskeleton:
Cdc42 (ACD03) and Rac1 (ARC03). Anti-Daam-1 was a kind gift
from Prof. Raymond Habas (Temple University, PA, USA.), while
phospho-Rap1GAP2 (Ser7) antibody was made as described [19].
Densitometry analysis was carried out using Image J 1.42q software
(http://rsb.info.nih.gov/ij/), normalising to the control, and is rep-
resentative of three independent experiments. Statistical analysis
was then performed on the resulting data using unpaired two-
tailed t-tests (GraphPad Prism v5.0).
2.4. Confocal microscopy
Platelets (2  104/lL) were activated for 30 s with 1.5 lM TRAP,
in the absence and presence of 50 nM WNT-3a, prior to ﬁxing in
3.7% paraformaldehyde. The ﬁxed platelets were adhered to un-
coated glass slides for 30 min. Slides were permeabilised in 0.1%
Triton-X100 before incubating with primary antibodies for anti-
Daam-1 (a kind gift from Prof. Raymond Habas) and anti-Dvl (sc-
25534, Santa Cruz), followed by an appropriate ﬂuorescent second-
ary antibody. All images were acquired using an Olympus FV1000
confocal microscope (Olympus Europa Germany).
2.5. Platelet spreading
Glass coverslips were coated overnight with 100 lg/ml ﬁbrino-
gen (Sigma, Arklow, Ireland) before blocking with BSA and mount-
ing in a live-cell microscopy chamber. Platelet (2  108/ml)adhesion and spreading was monitored by differential interference
contrast (DIC) microscopy with a wide-ﬁeld microscope DM IRB at-
tached to an ORCA ER camera (Leica, Wetzlar, Germany). Images
were processed with Volocity OpenLab 4.0.3 (Improvision, Wal-
tham, MA) to produce Quicktime videos of platelet spreading.
Adherence and spread platelet size was calculated using Image J
1.42q software (http://rsb.info.nih.gov/ij/) at 720 s with any plate-
let producing lamellipodia deemed ‘spread’.
3. Results
3.1. WNT-3a inhibits Rap1b activation by promoting Rap1GAP2
activity
Rap1b is a key intracellular signalling protein in platelets
known to control integrin aIIbb3-receptor activation and platelet
aggregation [3]. Since small GTPase activation occurs rapidly fol-
lowing agonist stimulation, and platelet aggregation has been pre-
viously shown to induce the inactivation of Rap1b [20], samples
were lysed after only 30 s in the absence of aggregation. We ob-
served no Rap1-GTP in resting platelets but found levels to increase
after 30 s of 1.5 lM TRAP activation (p = 0.0004) (Fig. 1A). Pre-
treating platelets with 32 or 50 nM WNT-3a prior to TRAP activa-
tion inhibited Rap1-GTP levels (p = 0.1446 and p = 0.0081, respec-
tively), while WNT-3a on its own had no effect. Since total Rap1
levels were found to remain stable, it is likely that WNT-3a is reg-
ulating the conversion of Rap1-GTP into its inactive GDP-bound
state.
As the only Rap1 GAP protein identiﬁed in platelets to date,
Rap1GAP2 plays a pivotal role in platelet Rap1b GTPase regulation
by converting it into an inactive GDP-bound form [18]. Phosphor-
ylation of Rap1GAP2 at Ser7, a residue present only in the platelet
splice variants of Rap1GAP2, is a known marker of GAP activity
[18]. Using a phospho-speciﬁc Ser7 antibody we observed only
background levels of Ser7 phosphorylation in resting and 1.5 lM
TRAP-activated platelets (Fig. 1B). However, when platelets were
pre-treated with 32 or 50 nM WNT-3a (p = 0.0510 and p = 0.0222,
respectively) prior to TRAP activation, we observed an increase in
Ser7 phosphorylation suggesting that WNT-3a may be promoting
Rap1GAP2 activity during platelet activation. This in turn may ex-
plain the reduction in Rap1b-GTP levels observed in Fig. 1A.
3.2. Increased Cdc42 and Rac1-GTP levels correlate with faster platelet
spreading over a ﬁbrinogen extracellular matrix
Small GTPase activation is also critical for platelet spreading
with Cdc42 implicated during ﬁlopodia formation [21] and Rac1
essential for lamellipodia production [22]. In washed platelets,
Cdc42-GTP levels peaked after 25 s in response to 1.5 lM TRAP
activation (solid line), before returning to basal levels (Fig. 2A).
Pre-treating platelets with 50 nM WNT-3a alone increased
Cdc42-GTP levels slightly (data not shown), while incubation for
30 s prior to TRAP stimulation (dotted line) was found to elevate
Cdc42-GTP levels across all time points, including resting platelets
(0 s), however this was statistically signiﬁcant only at 25 s
(p = 0.0281). We also observed Racl-GTP levels to increase during
WNT-3a treatment (Fig. 2B). Similar to the other small GTPases,
immunoblot analysis showed little Rac1 activation in resting plate-
lets. However, Rac1-GTP levels increased upon 1.5 lM TRAP activa-
tion (p = 0.0090) and were further increased in the presence of
WNT-3a (p = 0.0256).
Next we used a qualitative in vitro platelet spreading assay to
test the ability of washed platelets to adhere and spread on immo-
bilised ﬁbrinogen (Fb) (Fig. 2C) (videos in Supplementary informa-
tion). In the absence of WNT-3a, platelets adhere to Fb and produce
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Fig. 1. WNT-3a inhibits Rap1 activation by promoting Rap1GAP2 activity. Resting and 1.5 lM TRAP-activated platelets were prepared in the absence and presence of WNT-3a
before (A) Incubating with GST-RalGDS-RBD agarose beads to pull-down the active form of Rap1, or (B) immunoblotting for phosphorylated Rap1GAP2 (Ser7) levels.
Forskolin-treated platelets (10 lM) were used as the positive control (data not shown) and total Rap1 and a-actinin immunoblots show equal loading. Densitometry analysis
is from three independent experiments ± S.E.M. and represents the GTP-bound or phosphorylated protein level normalised for total Rap1 or a-actinin protein expression (⁄,
p < 0.05).
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let is fully spread and remains unchanged after 720 s (Fig. 2C(i)).
Following WNT-3a treatment, the total number of platelets adher-
ing to Fb was signiﬁcantly reduced (Fig. 2D; column 2), while the
remaining adherent platelets showed faster spreading in compari-
son to the control samples. These platelets displayed only transient
ﬁlopodia production, and had extensive lamellipodial formation
visible after only 180 s (Fig. 2C(iii) (180 s)). Analysis of the mean
surface area (Fig. 2D; column 3) revealed that platelets treated
with 32 or 50 nM WNT-3a were signiﬁcantly larger than the con-
trol platelets (p = 0.038 and p = 0.010, respectively). Furthermore,
instead of the centrally located granules seen under basal condi-
tions (Fig. 2C(i) (720 s)), WNT-3a treated platelets displayed an
abnormal granule distribution with a concave centre in the fully
spread platelet (Fig. 2C(iii) (720 s)). This did not change for the
remainder of the 30 min observation period. As microtubule rear-
rangement and actin assembly are essential for platelet shape
change it suggests a possible role for WNT-3a in modulating the
platelet cytoskeleton.
3.3. WNT-3a regulates RhoA-GTP activity via a Dvl/Daam-1 signalling
complex
In other cells, transmission of the WNT-3a signal via the Fzd
receptor regulates the interaction between Dvl Daam-1 [12]. We
have previously reported that Fzd4, Fzd6 and Dvl are all present
in human platelets. As we also found WNT-3a to reduce platelet
RhoA-GTP levels [6], we hypothesised a possible interaction be-
tween Dvl and Daam-1 in platelets. Using confocal microscopy,
we provide evidence for the interaction between Dvl and Daam-1
following 30 s of 1.5 lM TRAP stimulation (Fig. 3A). In the absence
of WNT-3a Dvl and Daam-1 co-localised in response to TRAP. How-
ever upon WNT-3a pre-treatment, while both proteins still reside
at the outer edge of the platelet, they do not appear to co-localise
to the same extent. Similarly, WNT-3a treatment alone was also
found to have no effect on Dvl/Daam-1 association (data not
shown). Next, we blotted Dvl immunoprecipitates with a Daam-
1-speciﬁc antibody (Fig. 3B). Similar to microscopy, there was nointeraction detected between these proteins when platelets were
in a resting state (0 s). However, Dvl co-immunoprecipitated with
Daam-1 within 30–60 s of TRAP activation (1.5 lM) and this inter-
action was inhibited when platelets were pre-treated with 50 nM
WNT-3a. Together these data propose that the Dvl/Daam-1 com-
plex plays a role during early platelet activation and shape change.
While the Dvl/Daam-1 complex is known to bind and activate
Rho-GTP in other cell types [12], it is unknown whether this occurs
in platelets. In the absence of WNT-3a, we found platelet RhoA-GTP
levels to increase following 30 s of TRAP (1.5 lM) stimulation be-
fore returning to basal levels at 60 s (Fig. 3C). This coincided with
a dramatic increase in Daam-1 binding to RhoA-GTP at 30 s and
to a lesser extent 60 s. These results are consistent with the Dvl/
Daam-1 complex forming 30 s after TRAP-activation (Fig. 3A and
B) suggesting that the Dvl/Daam-1 complex is a novel upstream
promoter of Rho-GTP activity in platelets. WNT-3a (50 nM) abol-
ished the effect of TRAP on both RhoA-GTP levels and Daam-1
binding to Rho-GTP. These ﬁndings are consistent with prior re-
ports showing that the WNT pathway controls Dvl/Daam1/Rho-
signalling in other cell types [12]. Total RhoA levels were found
to remain constant, suggesting that the WNT-mediated reduction
in RhoA-GTP is due toWNT-3a converting Rho-GTP into its inactive
GDP-bound state.
4. Discussion
In this study, we provide strong evidence that WNT-3a inﬂu-
ences platelet activation by regulating the activity of four key small
GTPase proteins; Rap1b, Cdc42, Rac1 and RhoA. Previously we
established that WNT-3a inhibited activation of the integrin aIIbb3
surface receptor, resulting in decreased platelet adhesion to Fb and
aggregation [6]. While aIIbb3 requires intracellular calcium signal-
ling for activation [23], we previously demonstrated that WNT-
3a inhibits platelets independent of altered Ca2+ mobilisation [6].
Our observation that WNT-3a inhibits Rap1b therefore provides a
viable alternative explanation for WNT-3a mediated inhibition of
inside-out activation of this major integrin on platelets. Since
Rap1b is carefully regulated by GAPs and GEFs, one could presume
(i) Untreated
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Fig. 2. Increased Cdc42 and Rac1-GTP levels correlates with faster platelet spreading over a ﬁbrinogen extracellular matrix. Resting and 1.5 lM TRAP-activated platelets were
used to measure (A) Cdc42-GTP levels by G-LISA in the absence (solid line) and presence (dotted line) of 50 nM WNT-3a or (B) Rac1-GTP levels using GST-PAK-PBD agarose
beads in the absence and presence of WNT-3a. Densitometry analysis is from three independent experiments and total Rac1 protein expression was used to normalise Rac1-
GTP levels. Results are presented as mean values ± S.E.M. (C) Resting platelets were allowed to spread over Fb in the absence and presence of WNT-3a, using differential
interference contrast microscopy. (D) Adherence and spread platelet size was calculated using Image J software. (⁄, p < 0.05).
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switch off GTPase function or inhibiting the GEFs that promote
small GTPase activity. Indeed, WNT signalling has been shown to
regulate GAP and GEF activity in other cells, with WNT-3a activat-
ing the Rac1 GEF Tiam-1 to increase Rac1-GTP levels in chondro-
cytes [24]. In platelets, we observed Ser7 phosphorylation of
Rap1GAP2 to increase during WNT signalling, although it remains
unclear why phosphorylation occurs only in the presence of TRAP
activation. Since phospho-Rap1GAP2 (Ser7) has previously been
linked to increased GAP activity [25], it suggests that WNT-3a
may be increasing Rap1 GAP activity during platelet activation
and offers a likely explanation for the lower Rap1b-GTP levels
and inhibition of integrin aIIbb3 activation and platelet aggregation
as described previously [6]. However, further work will be required
to directly prove that this is the case.
We also found WNT-3a to increase Cdc42 and Rac1-GTP levels
during platelet activation. Since Cdc42 is thought to be required
for ﬁlopodia growth [21], this may offer an explanation for the
rapid, transient ﬁlopodia formation observed during plateletspreading. However, recent studies suggest that ﬁlopodia forma-
tion can also occur independantly of Cdc42 [26]. In addition, acti-
vation of Rac1 is known to be essential for correct lamellipodia
formation [22]. Therefore, increased activation may explain the
faster, more extended platelet spreading observed with WNT-3a.
However, while WNT signalling would possibly reduce the number
of platelets adhering at sites of vascular damage, it remains unclear
why the rate and extent of platelet spreading would be increased
for the remaining adherent population and further work will be re-
quired to speciﬁcally understand this. Indeed a similar phenotype
has been reported in WNT-3a treated chondrocytes, where en-
hanced expression of the Rac1 GEF, Tiam-1, increased cell spread-
ing size [24]. A comparable phenotype has also been reported in
melanoma A7 cells lacking the FilGAP1 protein [27], which is a
Rac GAP protein activated downstream of RhoA. RhoA-GTP acti-
vates FilGAP1 which converts Rac1 into its GDP-bound form and
thus switches Rac1 activity off. Therefore, as WNT-3a also inhibits
RhoA activation, it may also reduce FilGAP1 levels or increase
Tiam-1 expression, either of which would increase Rac1 activation
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Fig. 3. WNT-3a regulates RhoA-GTP activity via a Dvl/Daam-1 signalling complex. Resting and 1.5 lM TRAP-activated platelets were prepared in the absence and presence of
50 nM WNT-3a before (A) Using confocal microscopy to investigate the cellular location of Daam-1 and Dvl, (B) Immunoprecipitating with Dvl antibody prior to blotting for
Daam-1 (Platelet Lysate (PL) was used as the positive control and anti-Dvl and anti-b-actin immunoblots show equal protein loading) or (C) incubating with GST-rhotekin-
RBD agarose beads to pull-down the active form of RhoA. GTPcS-treated platelet lysate was used as the positive control and total RhoA immunoblots show equal protein
loading across all sample lanes. All blots are representative of three independent experiments.
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spreading. This inverse Rho/Rac relationship has been noted previ-
ously during platelet activation [28] and both RhoA and Rac1 play
key roles during the WNT signalling response [29,30]. However,
since platelets cannot respond to changes in expression in the tra-
ditional sense (i.e., transcription–translation), further work will be
required to establish exactly howWNT signalling is producing such
effects on platelets as WNT-3a may affect post-translational mod-
iﬁcation of these signalling proteins or their compartmentalisation
within the platelet.
In this study, we also demonstrate that TRAP promotes the
binding of the WNT signalling protein Dvl to Daam-1 to control
downstream RhoA GTPase activity. The involvement of Dvl in the
platelet signalling response has not been previously demonstrated
however, Dvl has been shown to interact speciﬁcally with Ga13
during PAR1 activation in HEK cells [31], suggesting that this also
could be occurring in platelets. Further investigation will be re-
quired to establish whether this speciﬁc interaction is present in
the anucleate platelet and whether other platelet agonists are
capable of eliciting a similar Dvl/Daam-1 signalling response.
While we found WNT-3a to inhibit Dvl/Daam-1 binding during
platelet activation, in other cells WNT has an opposing effect, pro-
moting Dvl/Daam-1 binding to increase RhoA activation [12,29].
Such opposing cell-speciﬁc responses to WNT-3a have already
been demonstrated [32]. For example, WNT-3a activates gene tran-
scription in HUVEC cells [7], while in monocytes and THP-1 cells it
has no effect on TCF-promoter activity or the expression of classi-
cal WNT target genes [33,34]. Likewise, Daam-1 is not required for
WNT signalling in Drosophila [35], yet in Xenopus embryos Daam-1
is essential for WNT/Fzd/Dvl-dependent RhoA activation [12].Thus, WNT effectors can assemble to provide diverse and cell-spe-
ciﬁc signalling responses. This is especially relevant in the anucle-
ate platelet as any WNT-3a effect is independent of changes in
gene expression.
Taken together, our results demonstrate that WNT-3a differen-
tially modulates the downstream signalling activity of four key
GTPase proteins in platelets. We hypothesise that WNT-3a is most
likely regulating key GAPs and GEFs during platelet activation to
either suppress (Rho, Rap1b) or promote (Rac1, Cdc42) small
GTPase function. In conclusion, our data implicatesWNT and down-
stream WNT signalling effectors as novel upstream regulators of
small GTPase activity in platelets and represents a possible mecha-
nism through which WNT-3a signalling regulates platelet function.
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